

Block view of the study programme

Or Th Pr Au Cr

Block 1

Information

Professor Ph HUBERT
 Analytical chemistry
 B36 - 4000 Liege
 Phone number: 04/366 43 16
 e-mail address: Ph.Hubert@uliege.be

Collegiality

For ULiege: Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Philippe HUBERT, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.

For ULB: Patrick DI STEFANO, François DUFASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA.

For UCLouvain: Catherine DRUEZ, Laure ELENIS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.

Compulsory courses

| Code | Course Name | TA | Th | Pr | Au | Cr |
|--|---|--------------------------|----|----|----|----------|
| PHIN2034-1 | <i>Biotechnologies</i> | | | | | 7 |
| | - Concepts and production of protein and oligonucleotide biopharmaceuticals - David VERMIJLEN | 15 | - | - | | |
| | - Living biopharmaceuticals, vaccines and biosecurity - Véronique FONTAINE | 6 | - | - | | |
| | - Managing the risk of the release of cell and genetic products - Roland MARINI DJANG'EING'A | 3 | - | - | | |
| | - Formulation of biopharmaceuticals - Rita VANBEVER | 15 | - | - | | |
| | - Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part A - Marianne FILLET | 5 | - | - | | |
| | - Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part B (post-translational modifications) - Cédric DELPORTE | 3 | - | - | | |
| | - From the laboratory to the pharmacy: legal requirements - part a: Patents and industrial protection - Patrick DI STEFANO | 5 | - | - | | |
| | - From the laboratory to the pharmacy: legal requirements - part b: Statutes and regulatory constraints on biological products - Hugues MALONNE | 3 | - | - | | |
| | - From the laboratory to the pharmacy: legal requirements - part c: Procedure for releasing batches and the legal framework of vaccines - Lorenzo TESOLIN | 1 | - | - | | |
| | - From the laboratory to the pharmacy: legal requirements - part d: Organisation of quality assurance - Thierry PRONCE | 3 | - | - | | |
| | - From the laboratory to the pharmacy: legal requirements - part e: Introduction to Biobanking - Stéphanie GOFFLOT | 3 | - | - | | |
| | PHIN2004-1 | <i>Active substances</i> | | | | |
| - Substances issues de recherches pharmacochimiques, part a - Bernard PIROTTE | | 10 | - | - | | |
| - Substances issues de recherches pharmacochimiques, part b - François DUFASNE | | 5 | - | - | | |
| - Substances d'origine naturelle, part a - Joëlle LECLERCQ | | 5 | - | - | | |
| - Substances d'origine naturelle, part b - Caroline STEVIGNY | | 5 | - | - | | |
| - Produits radiopharmaceutiques - Zéna WIMANA | 10 | - | - | | | |
| PHIN2008-2 | <i>Clinical viewpoints</i> | | | | | 5 |
| | - Métabolisme des médicaments et paramètres pharmacocinétiques - FrançoisXavier MATHY | 20 | - | - | | |
| | - Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis RADERMECKER | 15 | - | - | | |

| | | | | | |
|------------|---|------|---|---|---------------|
| | - <i>Information et pharmacovigilance</i> - Raphaël DENOZ | 10 | - | - | |
| PHIN2013-2 | <i>Quality assurance and pharmaceutical management</i> | TA | | | 7 |
| | - <i>Principles of pharmaceutical management</i> - JeanMichel VAN DER HOFSTADT | 10 | - | - | |
| | - <i>Quality assurance, part a : basic concepts and quality assurance organisation</i> - Thierry PRONCE | 14,5 | - | - | |
| | - <i>Quality assurance, part b: analytical technology of procedures and risk analysis</i> - Xavier MARCELIS | 10 | - | - | |
| | - <i>English applied to the pharmaceutical industry</i> - Jacques POUPAERT, Nevin SERBEST | 20 | - | - | |
| | - <i>Pharmaceutical marketing</i> - Vincent BIERLAIRE | 7,5 | - | - | |
| PHIN2033-1 | <i>Pharmaceutical technology</i> | TA | | | 5 |
| | - <i>Industrial pharmaceutical microbiology</i> - Véronique FONTAINE | 9 | - | - | |
| | - <i>Preformulation and selection of galenical forms</i> - Jonathan GOOLE | 15 | - | - | |
| | - <i>Industrial production of galenical forms</i> - Brigitte EVRARD | 15 | - | - | |
| | - <i>Industrial aspects of technological development including packaging</i> - Laurence DENIS | 10 | - | - | |
| PHIN2023-1 | <i>Drug analysis</i> | TA | | | 6 |
| | - <i>Analytical control practices and pharmaceutical and biopharmaceutical control - part a</i> - Pierre VAN ANTWERPEN | 7 | - | - | |
| | - <i>Analytical control practices and pharmaceutical and biopharmaceutical control - part b</i> - Marianne FILLET | 5 | - | - | |
| | - <i>Pharmaceutical and biopharmaceutical analytical methods - Approving and certifying equipment</i> - Philippe HUBERT, Roland MARINI DJANG'EING'A | 12 | - | - | |
| | - <i>Pharmaceutical and biopharmaceutical analytical methods - Process Analytical Technology</i> - Eric ZIEMONS | 5 | - | - | |
| | - <i>Statistical methods applied to the pharmaceutical industry</i> - Laure ELENS | 15 | - | - | |
| | - <i>Experimental planning and quality by design</i> - Bruno BOULANGER, Pierre LEBRUN | 10 | - | - | |
| PHIN2029-2 | <i>Regulation and the medical-social environment</i> | TA | | | 8 |
| | - <i>Economic aspects of drug development</i> - Dominique MARTIN | 10 | - | - | |
| | - <i>Legislation and procedures applied to pharmaceutical industry</i> - Catherine DRUEZ | 10 | 5 | - | |
| | - <i>Patents and protection</i> - Patrick DI STEFANO | 5 | - | - | |
| | - <i>Macroeconomic environment and pharmaco-economics</i> - Hugues MALONNE | 7 | - | - | |
| | - <i>CTD File (Common Technical Document)</i> - Walid EL AZAB | 15 | - | - | |
| | - <i>Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files</i> - Karen VAN MALDEREN | 7,5 | - | - | |
| | - <i>Regulations of preclinical and clinical studies, part b : clinical studies</i> - Anne LENAERS | 5 | - | - | |
| | - <i>Regulations of preclinical and clinical studies, part c : pediatric studies</i> - Thierry SCHURMANS | 2,5 | - | - | |
| | - <i>Specific regulatory issues, part a : medicine and herbal dietary supplement</i> - Michel FREDERICH | 5 | - | - | |
| | - <i>Aspects réglementaires particuliers, partim b : Préformulation et documentation du développement galénique</i> - Francis VANDERBIST | 5 | - | - | |
| PHIN2032-1 | <i>Visits and seminars organised in the pharmaceutical industry</i> - François DUFRASNE, Marianne FILLET, Joëlle LECLERCQ, Rita VANBEVER - [75h Vis.] | TA | - | - | [+] 3 |
| MTFE2000-1 | <i>End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab</i> - François DUFRASNE, Philippe HUBERT, Joëlle LECLERCQ - [12w STCO] | TA | - | - | [+] 15 |